(Arg)9 acetate (Synonyms: Nona-L-arginine acetate; Peptide R9 acetate) |
Catalog No.GC66389 |
(Arg)9 (Nona-L-arginine) acetate는 9개의 아르기닌 잔기로 구성된 세포 침투 펩타이드(CPP)입니다. 821d96072c2d58d8970e76f526b0f6b8(Arg)9 아세테이트는 신경보호 특성을 가지며, 글루탐산 모델에서 0.78 μM의 IC50으로 신경보호 활성을 나타낸다.821d96072c2d58d8970e76f526b0f6b8
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
IC50: 0.78 μM (neuroprotection)[1]
(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC50 of 0.78 μM in the glutamic acid model[1][2].
(Arg)9 (Nona-L-arginine; 5-10 μM) acetate provides significant neuroprotection in a dose-response manner following glutamic acid exposure (IC50=0.78 μM). Following kainic acid exposure, (Arg)9 acetate is neuroprotective, but less effective than in the glutamic acid model (IC50=0.81 μM). (Arg)9 acetate also shows neuroprotection following in vitro ischemia (IC50=6 μM)[1].
(Arg)9 (Nona-L-arginine; 1 μM/kg (600 μL); i.v.; once, for 30min; male Sprague-Dawley ratspermanent middle cerebral artery stroke model) acetate shows neuroprotective effects and reduces infarct volume[2].
Animal Model: | Male Sprague-Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model[2] |
Dosage: | 1 μM/kg (600 μL) |
Administration: | Intravenous injection; once, over 5 minutes |
Result: | Reduced significantiy 20% in infarct volume. |
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *